MedTrace Logo

D-cycloserine (DCS) Pretreatment + CBT + Nicotine Replacement Therapy for Smoking Cessation (DCS)

NCT01842334 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2018-08-31

Study results available
· View outcomes & findings →

Summary

1. Compare the relative efficacy of ten weeks of once weekly 250 mg D-cycloserine (DCS) vs. placebo (both in conjunction with cognitive behavioral therapy (CBT) and nicotine replacement therapy (NRT) on reducing cigarette smoking in treatment-seeking nicotine-dependent outpatients.
2. Compare the relative efficacy of ten weeks of once weekly 250 mg DCS vs. placebo on the process of extinction and the memory encoding process.

Conditions

  • Nicotine Dependence
  • Smoking Cessation

Interventions

BEHAVIORAL

Cognitive Behavioral Therapy

CBT administered to to both DCS and placebo group.

DRUG

Nicotine Replacement Therapy

NRT administered to both DCS and placebo group.

Sponsors & Collaborators

  • American Lung Association

    collaborator OTHER

  • Mclean Hospital

    lead OTHER

Principal Investigators

  • Kevin P. Hill, MD, MHS · Mclean Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2017-08-31
Completion
2017-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01842334 on ClinicalTrials.gov